search
Back to results

A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
CKD-828, D064, D701
Sponsored by
Chong Kun Dang Pharmaceutical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

19 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Healthy adult aged ≥ 19 at screening Body mass index (BMI) of 17.5 kg/m2 or more and less than 30.5kg/m2 and Body weight ≥ 55kg Those who do not have congenital or chronic diseases and have no pathological symptoms or findings as a result of medical examination A person who is deemed suitable as a subject as a result of screening such as clinical laboratory examination (hematology, blood chemistry, urinalysis, serological tests, etc.), vital signs, electrocardiogram examination, etc. A person who has received a sufficient explanation of the purpose and contents of the clinical trial and has agreed in writing voluntarily to participate in the clinical trial A person who has agreed to use appropriate contraception and not donate sperm or eggs until 14 days after the first administration of the drug and the last administration of the drug Those who have the ability and willingness to participate during the entire study period Exclusion Criteria: A history of clinically significant blood, renal, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, liver, psychiatric, neurological, or immune disease (except for simple dental history of calculus, impacted teeth, wisdom teeth, etc.) or evidence on who has Those with a history of gastrointestinal diseases or surgery (expect simple appendicectomy, hernia surgery, and tooth extraction surgery) that may affect drug absorption ruler A person who shows the following values as a result of conducting a clinical laboratory test ALT or AST > 2 times the upper limit of the normal range Smokers who smoked more than 20 cigarettes a day within 6 months of screening Those who have taken other investigational product or bioequivalence investigational product within 6 months before the first administration of the investigational product Those who meet the following as a result of measuring vital signs at screening Those who have a systolic blood pressure of less than 90 mmHg or more than 140 mmHg or a diastolic blood pressure of less than 60 mmHg or more than 90 mmHg in the sitting position Severe bradycardia (less than 50 beats/min) Those with a history of regular alcohol intake within 1 month of screening More than 14 drinks/week for women More than 21 drinks/week for men A person who has taken a drug known to significantly induce or inhibit drug metabolizing enzymes within 30 days before the first administration of investigational product Those who have taken prescription or non-prescription drugs within 10 days prior to the first administration of investigational product Those who have donated whole blood within 2 months before the first administration of the investigational product, donated component blood within 1 month, received blood transfusion within 1 month, or have plans for the trial during the clinical trial period Those who are judged by the principal investigator (or the person in charge of the test who has been delegated) for reason other than the above selection/exclusion criteria and are judged unsuitable for participation in the study

Sites / Locations

  • Central hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Sequence 1

Sequence 2

Arm Description

Period 1: D064, D701 - A single oral dose of 2 tablets Period 2: CKD-828 - A single oral dose of 1 tablet Period 3: D064, D701 - A single oral dose of 2 tablets Period 4: CKD-828 - A single oral dose of 1 tablet

Period 1: CKD-828 - A single oral dose of 1 tablet Period 2: D064, D701 - A single oral dose of 2 tablets Period 3: CKD-828 - A single oral dose of 1 tablet Period 4: D064, D701 - A single oral dose of 2 tablets

Outcomes

Primary Outcome Measures

AUCt of CKD-828
Area under the concentration-time curve time zero to time
Cmax of CKD-828
Maximum plasma concentration of the drug

Secondary Outcome Measures

Full Information

First Posted
April 18, 2023
Last Updated
August 24, 2023
Sponsor
Chong Kun Dang Pharmaceutical
search

1. Study Identification

Unique Protocol Identification Number
NCT05834595
Brief Title
A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828
Official Title
An Open-label, Randomized, Fasted, Single-dose, 2-sequence, 4-period, Replicate Crossover Study to Compare the Pharmacokinetic and Safety Between Administration of CKD-828 20/2.5mg and Administration of D064, D701 in Healthy Adults
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
May 2, 2023 (Actual)
Primary Completion Date
July 18, 2023 (Actual)
Study Completion Date
July 26, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chong Kun Dang Pharmaceutical

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
A clinical trial to compare the pharmacokinetic and safety of CKD-828
Detailed Description
An open-label, randomized, fasted, single-dose, 2-sequence, 4-period, replicate crossover study to compare the pharmacokinetic characteristics and safety between administration of CKD-828 20/2.5mg and administration of D064, D701 in healthy adults

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
43 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sequence 1
Arm Type
Experimental
Arm Description
Period 1: D064, D701 - A single oral dose of 2 tablets Period 2: CKD-828 - A single oral dose of 1 tablet Period 3: D064, D701 - A single oral dose of 2 tablets Period 4: CKD-828 - A single oral dose of 1 tablet
Arm Title
Sequence 2
Arm Type
Experimental
Arm Description
Period 1: CKD-828 - A single oral dose of 1 tablet Period 2: D064, D701 - A single oral dose of 2 tablets Period 3: CKD-828 - A single oral dose of 1 tablet Period 4: D064, D701 - A single oral dose of 2 tablets
Intervention Type
Drug
Intervention Name(s)
CKD-828, D064, D701
Intervention Description
QD, PO
Primary Outcome Measure Information:
Title
AUCt of CKD-828
Description
Area under the concentration-time curve time zero to time
Time Frame
Pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, 72 hours
Title
Cmax of CKD-828
Description
Maximum plasma concentration of the drug
Time Frame
Pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, 72 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy adult aged ≥ 19 at screening Body mass index (BMI) of 17.5 kg/m2 or more and less than 30.5kg/m2 and Body weight ≥ 55kg Those who do not have congenital or chronic diseases and have no pathological symptoms or findings as a result of medical examination A person who is deemed suitable as a subject as a result of screening such as clinical laboratory examination (hematology, blood chemistry, urinalysis, serological tests, etc.), vital signs, electrocardiogram examination, etc. A person who has received a sufficient explanation of the purpose and contents of the clinical trial and has agreed in writing voluntarily to participate in the clinical trial A person who has agreed to use appropriate contraception and not donate sperm or eggs until 14 days after the first administration of the drug and the last administration of the drug Those who have the ability and willingness to participate during the entire study period Exclusion Criteria: A history of clinically significant blood, renal, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, liver, psychiatric, neurological, or immune disease (except for simple dental history of calculus, impacted teeth, wisdom teeth, etc.) or evidence on who has Those with a history of gastrointestinal diseases or surgery (expect simple appendicectomy, hernia surgery, and tooth extraction surgery) that may affect drug absorption ruler A person who shows the following values as a result of conducting a clinical laboratory test ALT or AST > 2 times the upper limit of the normal range Smokers who smoked more than 20 cigarettes a day within 6 months of screening Those who have taken other investigational product or bioequivalence investigational product within 6 months before the first administration of the investigational product Those who meet the following as a result of measuring vital signs at screening Those who have a systolic blood pressure of less than 90 mmHg or more than 140 mmHg or a diastolic blood pressure of less than 60 mmHg or more than 90 mmHg in the sitting position Severe bradycardia (less than 50 beats/min) Those with a history of regular alcohol intake within 1 month of screening More than 14 drinks/week for women More than 21 drinks/week for men A person who has taken a drug known to significantly induce or inhibit drug metabolizing enzymes within 30 days before the first administration of investigational product Those who have taken prescription or non-prescription drugs within 10 days prior to the first administration of investigational product Those who have donated whole blood within 2 months before the first administration of the investigational product, donated component blood within 1 month, received blood transfusion within 1 month, or have plans for the trial during the clinical trial period Those who are judged by the principal investigator (or the person in charge of the test who has been delegated) for reason other than the above selection/exclusion criteria and are judged unsuitable for participation in the study
Facility Information:
Facility Name
Central hospital
City
Gyeonggi-do
ZIP/Postal Code
15079
Country
Korea, Republic of

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828

We'll reach out to this number within 24 hrs